Twist Bioscience (TWST) Operating Income (2017 - 2026)

Twist Bioscience has disclosed Operating Income across 10 years of filings, most recently posting -$45.9 million for Q1 2026.

• In Q1 2026, Operating Income fell 10.35% year-over-year to -$45.9 million; the TTM figure through Mar 2026 stood at -$138.8 million (up 30.99% YoY), while the FY2025 annual figure was -$136.3 million, up 38.3% from the prior year.
• Operating Income declined to -$45.9 million in Q1 2026, from -$32.9 million in the prior quarter.
• Over the last five years, Operating Income for TWST reached as high as -$29.9 million in Q3 2025 and fell as low as -$88.9 million in Q2 2024.
• The 5-year median for Operating Income is -$47.0 million (2023), against an average of -$48.9 million.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 59.99% — and 2025, when it jumped 66.13%.
• A 5-year view of Operating Income shows it stood at -$44.6 million in 2022, then dropped by 5.26% to -$47.0 million in 2023, then grew by 26.25% to -$34.6 million in 2024, then gained by 5.03% to -$32.9 million in 2025, then sank by 39.4% to -$45.9 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$45.9 million, -$32.9 million, and -$29.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.